PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) have been assigned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $4.3333.

Several equities analysts have weighed in on PMVP shares. LADENBURG THALM/SH SH began coverage on PMV Pharmaceuticals in a report on Wednesday, July 8th. They set a “buy” rating and a $3.00 price target for the company. Weiss Ratings raised PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Oppenheimer lowered their target price on PMV Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a report on Friday.

Hedge Funds Weigh In On PMV Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Shay Capital LLC bought a new stake in shares of PMV Pharmaceuticals in the 2nd quarter worth about $26,000. Vanguard Group Inc. lifted its holdings in shares of PMV Pharmaceuticals by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,163,027 shares of the company’s stock valued at $3,028,000 after acquiring an additional 9,427 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of PMV Pharmaceuticals by 115.5% in the 3rd quarter. Bridgeway Capital Management LLC now owns 320,653 shares of the company’s stock valued at $449,000 after acquiring an additional 171,853 shares during the last quarter. Algert Global LLC bought a new position in shares of PMV Pharmaceuticals in the 3rd quarter valued at about $87,000. Finally, Boothbay Fund Management LLC purchased a new position in PMV Pharmaceuticals in the third quarter worth about $282,000. Institutional investors own 90.20% of the company’s stock.

PMV Pharmaceuticals Stock Down 1.6%

Shares of PMV Pharmaceuticals stock opened at $1.24 on Friday. The firm has a market cap of $66.29 million, a price-to-earnings ratio of -0.87 and a beta of 1.37. The business has a 50-day moving average price of $1.25 and a 200-day moving average price of $1.29. PMV Pharmaceuticals has a twelve month low of $1.02 and a twelve month high of $1.88.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.05. On average, equities analysts expect that PMV Pharmaceuticals will post -1.38 EPS for the current fiscal year.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.